drugset / Trial / NCT05279924

Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast

NCT05279924

NaSingle-groupOpen-labelTreatment

Summary

Assessment of the outcomes of prophylaxis with Emicizumab in children with severe hemophilia A in Ivory Coast

Timeline

Start
2021-07-01
Primary completion
2022-10-20
Completion
2022-10-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Emicizumab Monoclonal antibody

Indications